![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: MATN3 |
Gene summary for MATN3 |
![]() |
Gene information | Species | Human | Gene symbol | MATN3 | Gene ID | 4148 |
Gene name | matrilin 3 | |
Gene Alias | DIPOA | |
Cytomap | 2p24.1 | |
Gene Type | protein-coding | GO ID | GO:0001501 | UniProtAcc | O15232 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
4148 | MATN3 | HCC1_Meng | Human | Liver | HCC | 1.07e-08 | 3.84e-02 | 0.0246 |
4148 | MATN3 | S014 | Human | Liver | HCC | 9.77e-20 | 8.21e-01 | 0.2254 |
4148 | MATN3 | S015 | Human | Liver | HCC | 1.17e-24 | 1.07e+00 | 0.2375 |
4148 | MATN3 | S016 | Human | Liver | HCC | 3.00e-20 | 9.93e-01 | 0.2243 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
MATN3 | SNV | Missense_Mutation | rs368983587 | c.946N>A | p.Gly316Arg | p.G316R | O15232 | protein_coding | deleterious(0.03) | benign(0.077) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
MATN3 | SNV | Missense_Mutation | rs755692495 | c.284N>A | p.Arg95Gln | p.R95Q | O15232 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AX-A06F-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | SD |
MATN3 | SNV | Missense_Mutation | rs745976322 | c.1457N>A | p.Arg486His | p.R486H | O15232 | protein_coding | deleterious_low_confidence(0.02) | benign(0.006) | TCGA-AX-A1CE-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | SD |
MATN3 | SNV | Missense_Mutation | c.648N>T | p.Glu216Asp | p.E216D | O15232 | protein_coding | tolerated(0.06) | probably_damaging(0.999) | TCGA-B5-A11E-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
MATN3 | SNV | Missense_Mutation | c.1313G>T | p.Arg438Ile | p.R438I | O15232 | protein_coding | deleterious(0.01) | possibly_damaging(0.877) | TCGA-B5-A1MR-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
MATN3 | SNV | Missense_Mutation | novel | c.577A>G | p.Ile193Val | p.I193V | O15232 | protein_coding | tolerated(0.14) | benign(0.254) | TCGA-B5-A1MX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Hormone Therapy | megace | SD |
MATN3 | SNV | Missense_Mutation | novel | c.1226N>A | p.Gly409Glu | p.G409E | O15232 | protein_coding | tolerated(0.11) | possibly_damaging(0.859) | TCGA-B5-A3FA-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
MATN3 | SNV | Missense_Mutation | novel | c.864N>A | p.His288Gln | p.H288Q | O15232 | protein_coding | tolerated(0.29) | benign(0.413) | TCGA-B5-A3FA-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
MATN3 | SNV | Missense_Mutation | rs566567939 | c.1132N>A | p.Gly378Ser | p.G378S | O15232 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-BS-A0TE-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | PD |
MATN3 | SNV | Missense_Mutation | c.1310N>A | p.Arg437Gln | p.R437Q | O15232 | protein_coding | tolerated(0.1) | benign(0.009) | TCGA-BS-A0UF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |